Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Kronos Bio ( (KRON) ).
Kronos Bio, Inc. is undergoing a significant transformation with an 83% workforce reduction aimed at strategic cost containment by December 31, 2024, incurring an expected $3.7 million in severance expenses. Concurrently, Norbert Bischofberger resigns as CEO, with Deborah Knobelman stepping up as President and Interim CEO, receiving increased compensation and a special bonus tied to potential company control changes. These shifts indicate a pivotal moment for Kronos Bio amidst anticipated financial restructuring.
See more insights into KRON stock on TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Blackrock to Buy HPS for $12B to Fortify Alternative Investments Business
- Google Urges Appeals Court to Overturn App Store Change Ruling
- Symbotic Craters 36% on Financial Misstatements and 10-K Filing Delay
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
